Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Unintended target effect of anti-BCL-2 DNAi.

Ebrahim AS, Kandouz M, Emara N, Sugalski AB, Lipovich L, Al-Katib AM.

Cancer Manag Res. 2017 Sep 22;9:427-432. doi: 10.2147/CMAR.S139105. eCollection 2017.

2.

Protoporphyrin IX regulates peripheral benzodiazepine receptor associated protein 7 (PAP7) and divalent metal transporter 1 (DMT1) in K562 cells.

Okazaki Y, Glass J.

Biochem Biophys Rep. 2017 Feb 27;10:26-31. doi: 10.1016/j.bbrep.2017.02.007. eCollection 2017 Jul.

3.

Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.

Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ.

Mol Imaging. 2017 Jan-Dec;16:1536012117723256. doi: 10.1177/1536012117723256.

4.

Chronic Exposure to Malaria Is Associated with Inhibitory and Activation Markers on Atypical Memory B Cells and Marginal Zone-Like B Cells.

Ubillos I, Campo JJ, Requena P, Ome-Kaius M, Hanieh S, Rose H, Samol P, Barrios D, Jiménez A, Bardají A, Mueller I, Menéndez C, Rogerson S, Moncunill G, Dobaño C.

Front Immunol. 2017 Aug 21;8:966. doi: 10.3389/fimmu.2017.00966. eCollection 2017.

5.

Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma.

Fanzani A, Poli M.

Int J Mol Sci. 2017 Aug 7;18(8). pii: E1718. doi: 10.3390/ijms18081718. Review.

6.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.

PMID:
28592703
7.

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.

Decker TM, Kluge M, Krebs S, Shah N, Blum H, Friedel CC, Eick D.

Sci Rep. 2017 May 10;7(1):1684. doi: 10.1038/s41598-017-01943-6.

8.

BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis.

Horniblow RD, Bedford M, Hollingworth R, Evans S, Sutton E, Lal N, Beggs A, Iqbal TH, Tselepis C.

Cancer Sci. 2017 Jun;108(6):1135-1143. doi: 10.1111/cas.13234. Epub 2017 Jun 2.

9.

DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms.

Lemler DJ, Lynch ML, Tesfay L, Deng Z, Paul BT, Wang X, Hegde P, Manz DH, Torti SV, Torti FM.

Breast Cancer Res. 2017 Mar 7;19(1):25. doi: 10.1186/s13058-017-0814-9.

10.

Activated Oncogenic Pathway Modifies Iron Network in Breast Epithelial Cells: A Dynamic Modeling Perspective.

Chifman J, Arat S, Deng Z, Lemler E, Pino JC, Harris LA, Kochen MA, Lopez CF, Akman SA, Torti FM, Torti SV, Laubenbacher R.

PLoS Comput Biol. 2017 Feb 6;13(2):e1005352. doi: 10.1371/journal.pcbi.1005352. eCollection 2017 Feb.

11.

Integration of MicroRNA, mRNA, and Protein Expression Data for the Identification of Cancer-Related MicroRNAs.

Seo J, Jin D, Choi CH, Lee H.

PLoS One. 2017 Jan 5;12(1):e0168412. doi: 10.1371/journal.pone.0168412. eCollection 2017.

12.

Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin.

Truillet C, Cunningham JT, Parker MFL, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ.

Clin Cancer Res. 2017 Jun 15;23(12):3045-3052. doi: 10.1158/1078-0432.CCR-16-2448. Epub 2016 Dec 22.

PMID:
28007777
13.

PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.

Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, Meier P, Gris-Oliver A, Cheang MC, Perdrix-Rosell A, Shafat M, Noël E, Patel N, McEachern K, Scaltriti M, Castel P, Noor F, Buus R, Mathew S, Watkins J, Serra V, Marra P, Grigoriadis A, Tutt AN.

Nat Med. 2016 Nov;22(11):1303-1313. doi: 10.1038/nm.4198. Epub 2016 Oct 24. Erratum in: Nat Med. 2017 Jun 6;23 (6):788. Nat Med. 2017 Apr 7;23 (4):526.

14.

The Quest for Targets Executing MYC-Dependent Cell Transformation.

Hartl M.

Front Oncol. 2016 Jun 2;6:132. doi: 10.3389/fonc.2016.00132. eCollection 2016. Review.

15.

Iron and cancer: recent insights.

Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV.

Ann N Y Acad Sci. 2016 Mar;1368(1):149-61. doi: 10.1111/nyas.13008. Epub 2016 Feb 18. Review.

16.

BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis.

Richart L, Carrillo-de Santa Pau E, Río-Machín A, de Andrés MP, Cigudosa JC, Lobo VJ, Real FX.

Nat Commun. 2016 Jan 5;7:10153. doi: 10.1038/ncomms10153.

17.

MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis.

Kindrat I, Tryndyak V, de Conti A, Shpyleva S, Mudalige TK, Kobets T, Erstenyuk AM, Beland FA, Pogribny IP.

Oncotarget. 2016 Jan 12;7(2):1276-87. doi: 10.18632/oncotarget.6004.

18.

Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart.

Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC.

Cell Rep. 2015 Oct 20;13(3):533-545. doi: 10.1016/j.celrep.2015.09.023. Epub 2015 Oct 8.

19.

MYC, Metabolism, and Cancer.

Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV.

Cancer Discov. 2015 Oct;5(10):1024-39. doi: 10.1158/2159-8290.CD-15-0507. Epub 2015 Sep 17. Review.

20.

The habenula and iron metabolism in cerebral mouse models of multiple sclerosis.

Sands SA, Tsau S, LeVine SM.

Neurosci Lett. 2015 Oct 8;606:204-8. doi: 10.1016/j.neulet.2015.09.003. Epub 2015 Sep 8.

Supplemental Content

Support Center